Sanara MedTech Inc.
Close on Oct 19, 2026
- Market cap
- $287.08M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | $27.80M | $0.05 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 23, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $26.30M | $-3.40 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | $25.80M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 21, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $21.70M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on May 11, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| R&D | annual basis | 5% to 7% | – |
| net revenue | full year 2026 | $116.00M to $121.00M | New |
| growth | second quarter of 2026 | 10% to 14% growth | New |
| net revenue | second quarter of 2026 | $28.50M to $29.50M | New |
| growth | full year 2026 | 13% to 17% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Sanara MedTech filed with the SEC
MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)
Results of operations · EX-99.1 to Form 8-K
Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
Results of operations · EX-99.1 to Form 8-K
MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Reports Third Quarter 2025 Financial Results (Unaudited)
Results of operations · EX-99.1 to Form 8-K
MedTech Inc. Announces Strategic Realignment to Focus on Surgical Business
Results of operations · EX-99.1 to Form 8-K
MedTech Inc. Announces Chief Executive Officer Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)
Results of operations · EX-99.1 to Form 8-K
MedTech Inc. Expands Executive Leadership Team with New Appointments
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Reports Third Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · EX-99.2 to Form 8-K
MedTech Inc. Announces Changes to Its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. and InfuSystem Holdings, Inc. Announce Exclusive United States Distribution Agreement with, and Minority Investment in,
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MedTech Inc. Announces Second Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Announces First Quarter 2024 Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Executive or director change · EX-99.2 to Form 8-K
MedTech Inc. Announces $55 Million Debt Facility
Material agreement · Agreement terminated · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results
Results of operations · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · EX-99.2 to Form 8-K
MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023
Results of operations · EX-99.1 to Form 8-K
MedTech Inc. Announces Third Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Announces Second Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · EX-99.2 to Form 8-K
MedTech Inc. Announces the Acquisition of Certain Assets Related to its Collagen Products Business
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
MedTech Inc. Announces First Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K